Trial Profile
A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC-0156-0000-0009 When Used for Treatment and Prophylaxis of Bleeding Episodes in Patients With Haemophilia B
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs CCL2 LPM (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions
- Sponsors Osprey Pharmaceuticals
- 08 May 2014 New trial record